Drug Trial Radar · NCT03781986
APG-115 in Salivary Gland Cancer Trial
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
41
Actual
Start
Oct 28, 2019
Primary completion
Jan 19, 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- University of Michigan Rogel Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ascentage Pharma Group Inc.
- First posted
- Dec 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).
Conditions
- Malignant Salivary Gland Cancer
- Salivary Gland Cancer
Interventions
APG-115Drug
APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
CarboplatinDrug
Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Toxicity Endpoint: dose-limiting toxicity (DLT)Time frame: 42 days
- Maximally tolerated dose (MTD)Time frame: 42 days
- Overall response rateTime frame: up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida
University of Chicago
Chicago, Illinois
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.